Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Scientists in the USA have found a potential new target for treating people’s asthma.
Researchers wanted to find out whether SPLUNC1, a type of substance found in the body called a protein that is known to play a role in people with cystic fibrosis, could be involved in asthma.
In their study, published in the journal, Nature Communications, the scientists compared the sputum (phlegm) samples of people with asthma with those of people who do not have the condition. They found that the levels of this protein were very low in people who have asthma.
The researchers then looked at the levels of this protein in a group of mice who were given asthma-like symptoms. The levels were, again, low. Then, when the mice had their levels of the protein topped up, their asthma symptoms stopped.
Further research is needed to prove the link between this protein and asthma, but the researchers believe that their findings could pave the way for new treatment options.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79